ATAI vs. PRTA, ARQT, SAVA, GYRE, INVA, BCYC, VRNA, LQDA, OPK, and IRWD
Should you be buying Atai Life Sciences stock or one of its competitors? The main competitors of Atai Life Sciences include Prothena (PRTA), Arcutis Biotherapeutics (ARQT), Cassava Sciences (SAVA), Gyre Therapeutics (GYRE), Innoviva (INVA), Bicycle Therapeutics (BCYC), Verona Pharma (VRNA), Liquidia (LQDA), OPKO Health (OPK), and Ironwood Pharmaceuticals (IRWD). These companies are all part of the "pharmaceutical preparations" industry.
Atai Life Sciences (NASDAQ:ATAI) and Prothena (NASDAQ:PRTA) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, earnings, dividends, analyst recommendations, community ranking, risk, profitability, media sentiment and institutional ownership.
Atai Life Sciences has higher earnings, but lower revenue than Prothena. Atai Life Sciences is trading at a lower price-to-earnings ratio than Prothena, indicating that it is currently the more affordable of the two stocks.
Prothena has a net margin of -193.17% compared to Atai Life Sciences' net margin of -12,810.51%. Prothena's return on equity of -30.48% beat Atai Life Sciences' return on equity.
Atai Life Sciences has a beta of 0.92, suggesting that its share price is 8% less volatile than the S&P 500. Comparatively, Prothena has a beta of 0.3, suggesting that its share price is 70% less volatile than the S&P 500.
Atai Life Sciences presently has a consensus price target of $10.50, suggesting a potential upside of 532.53%. Prothena has a consensus price target of $67.00, suggesting a potential upside of 235.84%. Given Atai Life Sciences' stronger consensus rating and higher probable upside, equities research analysts clearly believe Atai Life Sciences is more favorable than Prothena.
28.4% of Atai Life Sciences shares are owned by institutional investors. Comparatively, 97.1% of Prothena shares are owned by institutional investors. 31.2% of Atai Life Sciences shares are owned by insiders. Comparatively, 28.1% of Prothena shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
In the previous week, Atai Life Sciences and Atai Life Sciences both had 5 articles in the media. Prothena's average media sentiment score of 1.04 beat Atai Life Sciences' score of 1.03 indicating that Prothena is being referred to more favorably in the news media.
Prothena received 274 more outperform votes than Atai Life Sciences when rated by MarketBeat users. Likewise, 70.67% of users gave Prothena an outperform vote while only 65.99% of users gave Atai Life Sciences an outperform vote.
Summary
Prothena beats Atai Life Sciences on 10 of the 17 factors compared between the two stocks.
Get Atai Life Sciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for ATAI and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ATAI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Atai Life Sciences Competitors List
Related Companies and Tools
